Aligos Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 6, 2025
ALGS$3.95-2.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share and per share data)
| March 31,2025 | December 31,2024 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $73,763 | $36,997 |
| Restricted cash | 110 | 110 |
| Short-term investments | 64,098 | 19,942 |
| Other current assets | 5,234 | 5,092 |
| Total current assets | 143,205 | 62,141 |
| Operating lease right-of-use assets | 4,648 | 4,964 |
| Property and equipment, net | 2,214 | 2,362 |
| Other assets | 632 | 627 |
| Total assets | $150,699 | $70,094 |
| LIABILITIES AND | ||
| STOCKHOLDERS’ EQUITY (DEFICIT) | ||
| Current liabilities: | ||
| Accounts payable | $4,460 | $2,571 |
| Accrued liabilities | 11,001 | 15,557 |
| Operating lease liabilities, current | 3,450 | 3,422 |
| Finance lease liabilities, current | 37 | 36 |
| Deferred revenue, current | - | 151 |
| Total current liabilities | 18,948 | 21,737 |
| Operating lease liabilities, net of current portion | 4,265 | 4,795 |
| Finance lease liabilities, net of current portion | 122 | 122 |
| 2023 common warrants liability | 10,873 | 72,367 |
| Long term liability | 46 | 46 |
| Total liabilities | 34,254 | 99,067 |
| Commitments and contingencies (Note 10) | ||
| Stockholders’ equity (deficit): | ||
| Preferred Stock, $0.0001 par value; 10,000,000 shares authorized as of March 31, 2025 and December 31, 2024, respectively; no shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively. | - | - |
| Common stock, $0.0001 par value; 20,800,000 shares and 20,800,000 shares authorized as of March 31, 2025 and December 31, 2024, respectively; 6,114,801 and 3,864,436 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively. | 9 | 8 |
| Additional paid-in capital | 690,909 | 588,576 |
| Accumulated deficit | (574,920) | (618,008) |
| Accumulated other comprehensive income | 447 | 451 |
| Total stockholders’ equity (deficit) | 116,445 | (28,973) |
| Total liabilities and stockholders’ equity (deficit) | $150,699 | $70,094 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.